Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2014
Business Overview: NanoViricides is a nano-biopharmaceutical company developing therapeutics for viral infections (e.g., Influenza, HIV, Ebola, Dengue) using proprietary nanoviricide technology. The company is in the pre-commercialization stage with no revenue to date. It holds exclusive, perpetual licenses from TheraCour Pharma, Inc. for its core technology.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2014 | Six Months Ended Dec 31, 2013 (Restated) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,029,444) | $(7,925,017) |
| Operating Expenses | $3,503,788 | $3,640,194 |
| Cash and Cash Equivalents (Dec 31, 2014) | $35,258,618 | $16,948,832 (Dec 31, 2013) |
| Total Assets | $47,605,018 | $43,859,995 (June 30, 2014) |
| Total Liabilities | $17,096,702 | $20,490,692 (June 30, 2014) |
| Stockholders' Equity | $30,508,316 | $23,369,303 (June 30, 2014) |
| Accumulated Deficit | $(52,930,845) | $(51,901,400) (June 30, 2014) |
Debt and Liquidity: The company holds significant convertible debentures (Series B and Series C) totaling approximately $6.57 million in principal value (net of discounts). Liquidity is strong with over $35 million in cash, sufficient for operations through at least December 31, 2016.
Material Changes vs. Prior Period
- Restatement of Financials: The company restated financial statements for periods ended June 30, 2014, and September 30, 2014, due to the failure to properly account for anti-dilution provisions in warrants and embedded derivatives in Series C debentures. This resulted in the reclassification of equity to derivative liabilities and adjustments to net loss.
- Net Loss Reduction: The net loss for the six months ended Dec 31, 2014 ($1.03M) was significantly lower than the prior year period ($7.93M). This improvement was primarily driven by a $3.4 million gain from the change in fair market value of derivative liabilities, offsetting operating losses.
- Asset Acquisition: The company purchased a cGMP-compliant manufacturing facility in Shelton, CT, from a related party (InnoHaven, LLC) for approximately $4.3 million (cost basis), increasing Property and Equipment significantly.
- Financing Activity: The company raised approximately $6.74 million through the exercise of old warrants in September 2014.
Outlook, Risks, and Management Commentary
- Drug Development Pipeline:
- FluCide: The most advanced candidate (Injectable and Oral) for influenza. Recent toxicology studies in rats showed a good safety profile. The company is scaling up production for IND-enabling studies.
- Ebola: The company restarted its anti-Ebola program in response to the West Africa epidemic. Drug candidates were shipped to a BSL-4 facility for testing in January 2015 (subsequent to the reporting period).
- Other Candidates: Includes DengueCide (Orphan Drug Designation), HIVCide, HerpeCide, and eye drops for viral conjunctivitis.
- Capital Requirements: Management estimates it has sufficient funds for over two years of operations. However, substantial additional financing will be required for full-scale manufacturing and clinical trials. The company plans to pursue non-dilutive funding (grants/contracts) and potential licensing deals.
- Risks and Contingencies:
- Going Concern: While currently liquid, the company has an accumulated deficit and no revenue. Future profitability is not guaranteed.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting regarding the accounting of complex debt and equity transactions, leading to the restatements. Remediation plans are underway.
- Legal Proceedings: A lawsuit regarding inspection of books and records (Yidam, Ltd. v. NanoViricides) was settled in September 2014 with a $150,000 reimbursement to the plaintiff.
Investor Verification Checklist
- Restatement Details: Verify the specific impact of the accounting error regarding derivative liabilities on the balance sheet and equity.
- Related Party Transactions: Review the terms of the facility purchase from InnoHaven, LLC (controlled by a significant shareholder) and the $9 million in debentures held by Director Milton Boniuk.
- Cash Burn Rate: Confirm the sustainability of the $35M cash balance against the projected $22M+ in expenses over the next 24 months.
- Derivative Liability Volatility: Assess the impact of future stock price fluctuations on the fair value of derivative liabilities, which significantly impacts reported net income/loss.
- Clinical Milestones: Monitor the results of the anti-Ebola testing and the toxicology studies for FluCide, as these are critical for future funding and valuation.